MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million.

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

Maze Therapeutics ( NASDAQ: MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated price ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

The breakthrough in AI technology by Chinese startup DeekSeek's r1 model has the potential to benefit the software sector, ...

BROOMFIELD, CO - January 17, 2025 (NEWMEDIAWIRE) - Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON ... the closing of an underwritten public offering of 100,000 shares of common ...

During the last three months, 11 analysts shared their evaluations of Keros Therapeutics (NASDAQ:KROS), revealing ... state of the company. Rating: Offering insights into predictions, analysts ...

Ribbon Acquisition Corp successfully closed its initial public offering of 5,000,000 units, raising significant capital at a price of $10.00 per unit. The units are now listed on The NASDAQ ...